Alert detail

LCD L40022: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — WPS

Policy ID: LCD-L40022Specialty: HematologyAdded: 6/5/2026Effective: August 17, 2025lcd
Routine

What changed

New LCD on non-NGS tests for myeloproliferative neoplasms.

Who’s affected: Hematology billing teams · Effective: August 17, 2025

Affected codes

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

This change affects 13 billing codes.

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Hematology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Hematology audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Hematology— the week’s changes and deadlines, delivered to your inbox. No account required.

LCD L40022: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — WPS